HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 1119-1128

  Putcharoen, Opass ^a,b,c   Lee, Sun Hee ^a,d   Henrich, Timothy J ^a,e   Hu, Zixin ^a   Vanichanan, Jakapat ^f   Coakley, Eoin ^g   Greaves, Wayne ^h   Gulick, Roy M ⁱ   Kuritzkes, Daniel R ^a,e   Tsibris, Athe M N ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^d Pusan National University School of Medicine   (South Korea)

^e HARVARD MEDICAL SCHOOL   (United States)

^f METROWEST MEDICAL CENTER   (United States)

^g MONOGRAM BIOSCIENCES   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; GLYCOPROTEIN GP 120; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; VICRIVIROC;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BIOACCUMULATION; CASE REPORT; CD4+ T LYMPHOCYTE; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MICROBIAL KINETICS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TARGET CELL; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

AMIDES; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MUTATION; PIPERAZINES; PYRIMIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84863116880     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06421-11     Document Type: Article

References (63)

1. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. 2009. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 106:18-5323.
2. Archer J, et al. 2009. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23:09-1218.
3. Ball SC, et al. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77:21-1038.
4. Cavrois M, De Noronha C, Greene WC. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 20:51-1154.
5. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC. 2004. HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 328:36-44.
6. Delobel P, et al. 2010. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. AIDS 24:82-1384.
7. Drummond AJ, et al. 2011. Geneious, v5.4.6. Biomatters Ltd., Auckland, New Zealand.
8. Frey S, et al. 1995. Temperature dependence of cell-cell fusion induced by the envelope glycoprotein of human immunodeficiency virus type 1. J. Virol. 69:1462-1472.
9. Garcia-Perez J, et al. 2011. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J. Biol. Chem. 286:4978-4990.
10. Gulick RM, et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:29-1441.
11. Gulick RM, et al. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 196:304-312.
12. Henrich TJ, et al. 2010. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J. Acquir. Immune Defic. Syndr. 55: 420-427.
13. Heredia A, et al. 2008. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc. Natl. Acad. Sci. U. S. A. 105:20476-20481.
14. Johnston SH, et al. 2009. A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. J. Virol. 83:016-11026.
15. Kirchherr JL, et al. 2007. High throughput functional analysis of HIV-1 env genes without cloning. J. Virol. Methods 143:4-111.
16. Kuhmann SE, Platt EJ, Kozak SL, Kabat D. 2000. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74:05-7015.
17. Kuhmann SE, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J. Virol. 78:90-2807.
18. Kwong PD, Wyatt R, Sattentau QJ, Sodroski J, Hendrickson WA. 2000. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J. Virol. 74:61-1972.
19. Lassen KG, et al. 2009. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog. 5:e1000377.
20. Lin NH, et al. 2010. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J. Virol. Methods 169:39-46.
21. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:9-113.
22. Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. 2004. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J. Virol. 78:28-4637.
23. Maeda K, et al. 2006. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281:688-12698.
24. Marozsan AJ, et al. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338:2-199.
25. Marozsan AJ, et al. 2005. Differences in the fitness of two diverse wildtype human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 79:7121-7134.
26. McNicholas P, et al. 2010. Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial. J. Infect. Dis. 201:1470-1480.
27. McNicholas PM, et al. 2011. Mapping and characterization of vicriviroc resistance mutations from human immunodeficiency virus type-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1). J. Acquir. Immune Defic. Syndr. 56:222-229.
28. Melikyan GB, et al. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413-423.
29. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. 2009. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell 137:3-444.
30. Miyauchi K, Kozlov MM, Melikyan GB. 2009. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation. PLoS Pathog. 5:e1000585.
31. Mkrtchyan SR, et al. 2005. Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J. Virol. 79:161-11169.
32. Moore JP, Kitchen SG, Pugach P, Zack JA. 2004. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 20:1-126.
33. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250: 1139-1142.
34. Ogert RA, et al. 2010. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology 400:5-155.
35. Ogert RA, et al. 2008. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373: 387-399.
36. + T cells. J. Virol. 84:05-6514.
37. Platt EJ, Durnin JP, Kabat D. 2005. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus. J. Virol. 79:4347-4356.
38. Platt, E. J., S. L. Kozak, J. P. Durnin, T. J. Hope, and D. Kabat. 2010. Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions. J. Virol. 84:06-3110.
39. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72: 55-2864.
40. Pugach P, et al. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361: 2-228.
41. Pugach P, et al. 2009. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology 387:296-302.
42. Rangel HR, et al. 2003. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J. Virol. 77:9069-9073.
43. Ray N, Blackburn LA, Doms RW. 2009. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. 83: 2989-2995.
44. Reeves JD, et al. 2002. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl. Acad. Sci. U. S. A. 99:16249-16254.
45. Reeves JD, et al. 2005. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J. Virol. 79:91-4999.
46. Reeves JD, et al. 2004. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J. Virol. 78:76-5485.
47. Strizki JM, et al. 2005. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49:4911-4919.
48. Tilton JC, et al. 2010. HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res. Hum. Retroviruses 26:13-24.
49. Trkola A, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. U. S. A. 99:395-400.
50. Troyer RM, et al. 2009. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 5:e1000365.
51. Tsamis F, et al. 2003. Analysis of the mechanism by which the smallmolecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77:01-5208.
52. Tsibris AM, et al. 2009. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 4:e5683.
53. Tsibris AM, Kuritzkes DR. 2007. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58:445-459.
54. Tsibris AM, et al. 2008. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J. Virol. 82:8210-8214.
55. U.S. Food and Drug Administration. 24 April 2007. Maraviroc tablets NDA 22-128: Antiviral Drugs Advisory Committee (AVDAC) briefing document, p 104. http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing /2007-4283b1-01-Pfizer.pdf. U.S. Food and Drug Administration, Rockville, MD.
56. Watson C, Jenkinson S, Kazmierski W, Kenakin T. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67:68-1282.
57. Weiss CD, Levy JA, White JM. 1990. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J. Virol. 64:74-5677.
58. Westby M, et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:09-4920.
59. Westby M, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81: 59-2371.
60. Wu L, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:9-183.
61. Wu L, et al. 1997. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186:73-1381.
62. Xu Y, Zhang X, Matsuoka M, Hattori T. 2000. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 487:5-188.
63. Zhu P, et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.